SNAP40-ED: Detection of physiological deterioration by the SNAP40 wearable device compared to standard monitoring devices in the Emergency Department.
SNAP40 is a device that monitors vital signs. It is small, portable and has no leads or wires, allowing for patients vital signs to be continuously monitored anywhere in the department. The device is smaller than most mobile phones, and is held within a blue casing attached to an armband (please see image). When fitted to a patient’s arm, the device will continuously monitor their vital signs whilst they are in the Emergency Department.
SNAP40 uses artificial intelligence algorithms to analyse data provided by its sensors in order to recognise indicators of health deterioration. The raw data collected by the sensors is converted into vital signs, which are analysed for signs of deterioration. An alert will be sent to staff if the device detects any signs of deterioration in the patient’s readings.
Sponsor: SNAP40, Forth Street, Edinburgh (UK)
Setting: This is a single centre study being co-ordinated from Edinburgh.
This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.
Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial
Randomised controlled Trial using smart phone based event recorder technology versus standard care in palpatations or pre-syncope
Traumatic Brain Injury (TBI) is the leading cause of death and disabilities amongst young people worldwide. Many sufferers develop chronic physical and mental health problems and are unable to work or re-engage socially after their injuries. There are therefore significant health and socioeconomic consequences.
A study examining the Prevalence and Risk of Anterior Pituitary Dysfunction following Traumatic Brain Injury